To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release oral formulation in early or advanced Parkinson's disease (PD)
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, ...
Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson&rsquo...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release o...
Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, ...
Angelo Antonini¹, Daniela Calandrella²¹Department for Parkinson&rsquo...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
International audienceIntermittent or pulsatile dopamine-receptor stimulation is postulated to induc...
Abstract Background Real-world impact of extended-release formulations of oral drugs should ideally ...
DOI
Add to ORKG